Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 6—June 2021

Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA

Mariana M. Lanata1, Huanyu Wang, Kathy Everhart, Melisa Moore-Clingenpeel, Octavio Ramilo, and Amy LeberComments to Author 
Author affiliation: Nationwide Children’s Hospital, Columbus, Ohio, USA

Main Article

Table 5

Risk factors for pediatric intensive care unit admission in children infected with Mycoplasma pneumoniae, Ohio, USA, 2015–2019*

Risk factor
Univariate analysis
OR (95% CI)
p value
Female sex 1.13 (0.5–2.55) 0.7754
Age, y 0.98 (0.9–1.08) 0.7206
Underlying condition 4.32 (1.72–10.88) 0.0019
Any previous visit 3.73 (1.31–10.62) 0.0138
Macrolide resistance 5.34 (1.39–20.55) 0.015
Abnormal respiratory examination 5.34 (1.41–20.21) 0.0137
Previous treatment with antimicrobial drugs 3.17 (1.38–7.27) 0.0066
Previous nonmacrolide antimicrobial drugs 2.81 (1.23–6.42) 0.014
Positive viral test 0.79 (0.31–2.01) 0.6127
MRMp and positive viral test 2.11 (0.27–16.71) 0.4805

*Bold type indicates statistical significance. MRMp, macrolide-resistant Mycoplasma pneumoniae; OR, odds ratio.

Main Article

1Current affiliation: Marshall University, Huntington, West Virginia, USA.

Page created: March 30, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.